Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.
Antibiotic treatment of lung infections may lead to the emergence of resistance in the gut flora. Appropriate dosing regimens could mitigate this adverse effect. In gnotobiotic rats harboring intestinal Escherichia coli and Enterococcus faecium populations, a lung infection by Klebsiella pneumoniae was instigated with two different sizes of inoculum to represent an early or a late initiation of antibiotic treatment. The rats were treated with marbofloxacin, an expanded-spectrum fluoroquinolone, by a single-shot administration or a fractionated regimen over 4 days. Intestinal bacterial populations were monitored during and after treatment. At the infection site, bacterial cure without any selection of resistance was observed. Whatever the dosage regimen, fluoroquinolone treatment had a transient negative impact on the E. coli gut population but not on that of E. faecium. The intestinal flora was colonized by the pathogenic lung bacteria, and there was the emergence of intestine-resistant K. pneumoniae, occurring more often in animals treated with a single marbofloxacin dose than with the fractionated dose. Bacterial cure without resistance selection at the infection site with fluoroquinolone treatment can be linked to colonization of the digestive tract by targeted pulmonary bacteria, followed by the emergence of resistance.
Kesteman
Anne-Sylvie
AS
UMR181 Physiopathologie et Toxicologie Expérimentales, INRA, ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des Capelles, BP 87 614, 31076 Toulouse Cedex 3, France.
Perrin-Guyomard
Agnès
A
Laurentie
Michel
M
Sanders
Pascal
P
Toutain
Pierre-Louis
PL
Bousquet-Mélou
Alain
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use; D007422:Intestines / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000187:drug effects*; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology*; D008297:Male; D051381:Rats
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C080260:marbofloxacin
JAMA. 2003 Feb 19;289(7):885-8
12588273
Lancet Infect Dis. 2001 Sep;1(2):101-14
11871461
Infect Immun. 1979 Jul;25(1):366-75
478640
Antimicrob Agents Chemother. 2009 Mar;53(3):1287-9
19064895
Res Vet Sci. 2006 Jun;80(3):324-35
16126240
JAMA. 1999 Feb 10;281(6):517-23
10022107
Clin Infect Dis. 2001 Jan;32(1):162-6
11112677
Antimicrob Agents Chemother. 2003 Nov;47(11):3610-2
14576127
J Vet Pharmacol Ther. 2004 Oct;27(5):283-8
15500564
Antimicrob Agents Chemother. 2008 Sep;52(9):3457-60
18606843
Antimicrob Agents Chemother. 2005 Aug;49(8):3513-6
16048971
Nagoya J Med Sci. 1999 May;62(1-2):11-28
10504824
Eur J Clin Microbiol Infect Dis. 1996 Apr;15(4):281-5
8781877
Microb Drug Resist. 2006 Spring;12(1):50-8
16584309
J Infect Dis. 2007 May 15;195(10):1480-8
17436228
J Vet Pharmacol Ther. 1996 Feb;19(1):56-61
8992027
Ann Intern Med. 2002 Jun 4;136(11):834-44
12044132
Clin Infect Dis. 2004 Jul 15;39(2):219-26
15307031
Antimicrob Agents Chemother. 2009 Aug;53(8):3384-90
19487439
Trends Microbiol. 2008 Mar;16(3):107-14
18280160
Rev Infect Dis. 1979 Sep-Oct;1(5):736-53
396632
Res Vet Sci. 2007 Jun;82(3):398-404
17118414
Antimicrob Agents Chemother. 2009 Nov;53(11):4740-8
19738020